Rybelsus becomes the first GLP-1 pill approved in the US for type 2 diabetes

The FDA approved Rybelsus (semaglutide) tablets on September 20, 2019, giving adults with type 2 diabetes the first GLP-1 receptor agonist they could swallow instead of inject ^[1][3][6]. Agency records show the application was handled on a priority review timeline ^[6]. Novo Nordisk makes the drug ^[1].

The approval covers use alongside diet and exercise to improve blood sugar control ^[1][3][5]. The active molecule, semaglutide, is the same one used in the injectable medicines Ozempic and Wegovy, but the label says the tablet is not substitutable on a milligram-for-milligram basis with those products ^[4][5].

Taking this tablet is not like swallowing an ordinary pill. Instructions call for one dose each morning on an empty stomach, with no more than 4 ounces of plain water — no coffee, juice or other liquids ^[1][5]. Then comes a waiting period: at least 30 minutes before any food, any drink or any other oral medicine ^[1][5]. The tablet has to go down whole; splitting, crushing, chewing or dissolving it in liquid is not allowed ^[5]. The strengths approved in 2019 were 3 mg, 7 mg and 14 mg ^[1][3][5].

Nausea, abdominal pain, diarrhea, decreased appetite, vomiting and constipation were the most common side effects, each reported in at least 5% of patients ^[1][5]. The label carries a boxed warning about thyroid C-cell tumors that appeared in rodents at clinically relevant exposures; whether the effect occurs in people is unknown, and the drug is contraindicated for patients with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2 ^[5]. Other listed precautions include acute pancreatitis, diabetic retinopathy complications, low blood sugar when used with insulin or insulin secretagogues, acute kidney injury from volume depletion, severe gastrointestinal reactions, serious allergic reactions and pulmonary aspiration during general anesthesia or deep sedation ^[1][5].

European reviewers examined the same drug. Novo Nordisk filed with the European Medicines Agency on April 26, 2019, and the CHMP assessment report was adopted on January 30, 2020 ^[2]. Reviewers there questioned the choice of 14 mg as the top dose, noting that 40 mg had a markedly stronger effect on HbA1c than 10 mg and that no clear argument for the 14 mg ceiling appeared in the filing ^[2]. The report also records a non-inferiority margin of 0.4% used in comparisons with empagliflozin and liraglutide, wider than the 0.3% the committee had advised ^[2].

Why it matters for patients

For years, this drug class meant injections. The 2019 decision added a needle-free route to the same category of medicine for type 2 diabetes ^[1][3]. The catch is scheduling. The empty-stomach rule and the 30-minute buffer apply to food, beverages and all other oral drugs, including ones that need close monitoring, according to the label ^[1][5]. Anyone already juggling several morning medicines faces a routine that is less forgiving than a once-weekly shot ^[5]. At the time, weight reduction was not an approved use of Rybelsus; the indication was type 2 diabetes ^[1][3].

What happened next

The label expanded over the following years. On January 12, 2023, the FDA cleared an update allowing Rybelsus to be used as a first-line option for adults with type 2 diabetes ^[1][3]. A second formulation, with 1.5 mg, 4 mg and 9 mg tablets, won approval on December 9, 2024 ^[1][3]. On October 17, 2025, the agency added cardiovascular risk reduction — lowering the chance of cardiovascular death, non-fatal heart attack or non-fatal stroke — in adults with type 2 diabetes at high risk of those events ^[1][3][6]. Then, on January 30, 2026, the FDA approved relabeling that newer formulation as Ozempic (semaglutide) tablets ^[1][3][4], with Novo Nordisk saying the Ozempic pill would reach the US market in the second quarter of 2026 ^[1][3][4]. The original 3 mg, 7 mg and 14 mg tablets continue under the Rybelsus name ^[1][3][5].